Is the version of Revumenib from Laos’ second pharmaceutical company reliable?

As of now, there is no officially approved generic version of Revumenib (Revumenib), including the version produced by the so-called "Laos Second Pharmaceutical Factory". Therefore, most of the "Lao version of Revimenil" appearing on the market are drugs circulated through informal channels, and their sources, ingredients, processes, efficacy and safety lack authoritative verification. According to the global drug regulatory database and public channels, it was not found that the second pharmaceutical factory in Laos has obtained the production authorization or legal registration of Revemenib.

Revimenib is an oral Menin inhibitor developed by the American biopharmaceutical company Syndax and is mainly used for treatment KMT2A rearrangement or NPM1 mutation in acute leukemia (AML/ALL). This type of targeted drugs has complex mechanisms and has extremely high requirements on the purity of raw materials, synthesis routes, bioavailability, etc., and the production process is much higher than that of ordinary small molecule drugs. Therefore, even if the ingredients of unauthorized generic versions are similar, it is difficult to guarantee that they will achieve the same level of efficacy and toxicity control as the original drug.

Using the unproven "Lao version" of Revimenib may be risky. First, drugs may contain impurities, or the dosage of active ingredients may be inaccurate; secondly, key pharmacokinetic parameters such as absorption rate and half-life are unknown, which may lead to weakened efficacy or increased toxic side effects; thirdly, the use of such drugs lacks clinical monitoring data support, making it difficult for doctors to judge and deal with them in a timely manner if adverse reactions occur during the medication period.

To sum up, the so-called "Lao No. 2 Pharmaceutical Factory's version of Revimeni" currently on the market does not have official legality and reliable clinical data support, the efficacy cannot be guaranteed, and the use risk is high. It is recommended that patients who need to use revimenib should give priority to obtaining overseas original drugs or participating in international multi-center clinical trials, and conduct systemic treatment under the guidance of professional hematology oncologists. Do not buy or take generic drugs from unknown sources without permission to avoid delaying your condition or causing irreversible health risks.

Reference materials:https://www.drugs.com/